Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-23T19:22:24.860Z Has data issue: false hasContentIssue false

The Effects of Deep-brain Magnetic Stimulation (DMS) on White Matter Deficits: New Mechanism in Major Depressive Disorder (MDD) Treatment

Published online by Cambridge University Press:  23 March 2020

Y. Zhang
Affiliation:
University of Saskatchewan, Department of Psychiatry, Saskatoon, Canada
D. Zhang
Affiliation:
University of Alberta, Department of Psychiatry, Edmonton, Canada
S. Feng
Affiliation:
Fourth Military Medical University, Department of Psychiatry, Xi’An, China
H. Guo
Affiliation:
University of Alberta, Department of Psychiatry, Edmonton, Canada
H. Zhang
Affiliation:
Xinxiang Medical University, Department of Psychology, Xinxiang, China
R. Bowen
Affiliation:
University of Saskatchewan, Department of Psychiatry, Saskatoon, Canada
X.M. Li*
Affiliation:
University of Alberta, Department of Psychiatry, Edmonton, Canada
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Deep-brain magnetic stimulation (DMS) is an effective therapy for various neuropsychiatric disorders including major depression disorder. The molecular and cellular mechanisms underlying the impacts of DMS on the brain remain unclear. Studies have reported abnormalities in the white matter of depressive brains, suggesting the involvement of myelin and oligodendrocyte pathologies in the development of major depressive disorder. In this study, we use a cuprizone induced demyelination animal model to generate depressive like behaviours and white matter and oligodendrocyte damages. Meanwhile, we treated the animal with DMS 20 minutes daily during the cuprizone challenge or recovery period. Behavioural tests, including nesting, new objective recognition, working memory and depression-like behaviours were tested periodically. Histological staining and western blotting were used to examine the underlying mechanism of DMS. We found that DMS reverse cuprizone induced behavioural deficits in acute demyelination but not during the recovery period. DMS alleviated demyelination and inflammation induced by cuprizone. During the recovery period, DMS had no impacts on overall neural progenitor cell proliferation, but enhanced the maturation of oligodendrocyte. This data suggest that DMS may be a promising treatment option for improving white matter function in psychiatric disorders and neurological diseases in future.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
Oral communications: Rehabilitation and psychoeducation and schizophrenia and other psychotic disorders
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.